daunorubicin

Ligand id: 7063

Name: daunorubicin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 5
Rotatable bonds 4
Topological polar surface area 185.84
Molecular weight 527.18
XLogP -1.07
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Daunorubicin is indicated for treatment of remissions of acute myelogenous and lymphocytic leukemias and may also be used to treat HIV-associated Kaposi's sarcoma. In the EU, daunorubicin is indicated for use only in orphan disease, namely acute myeloid leukemia. In August 2017 the US FDA approved a fixed-dose combination of daunorubicin and cytarabine (Vyxeos®) for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Mechanism Of Action and Pharmacodynamic Effects
Daunorubicin's cytotoxic action is due to its ability to cause DNA damage. The DNA damage is caused by several mechanisms, including intercalation in to DNA, strand breakage and inhibition of topoisomerase II. The DNA damage results in cell death.
External links